These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27567833)

  • 1. Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma.
    Pérez-Grijalba V; Fandos N; Canudas J; Insua D; Casabona D; Lacosta AM; Montañés M; Pesini P; Sarasa M
    J Alzheimers Dis; 2016 Sep; 54(2):751-62. PubMed ID: 27567833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
    Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
    Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Amyloid Concentration in Alzheimer's Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer's Disease Cases from Controls.
    Feinkohl I; Schipke CG; Kruppa J; Menne F; Winterer G; Pischon T; Peters O
    J Alzheimers Dis; 2020; 74(4):1285-1294. PubMed ID: 32176645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplex immunoassay measurement of amyloid-β
    Vogelgsang J; Shahpasand-Kroner H; Vogelgsang R; Streit F; Vukovich R; Wiltfang J
    Exp Brain Res; 2018 May; 236(5):1241-1250. PubMed ID: 29480353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease.
    Kim HJ; Park KW; Kim TE; Im JY; Shin HS; Kim S; Lee DH; Ye BS; Kim JH; Kim EJ; Park KH; Han HJ; Jeong JH; Choi SH; Park SA
    J Alzheimers Dis; 2015; 48(4):1043-50. PubMed ID: 26444752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment.
    Blennow K; De Meyer G; Hansson O; Minthon L; Wallin A; Zetterberg H; Lewczuk P; Vanderstichele H; Vanmechelen E; Kornhuber J; Wiltfang J; ; Heuser I; Maier W; Luckhaus C; Rüther E; Hüll M; Jahn H; Gertz HJ; Frölich L; Hampel H; Pernetzki R
    J Nutr Health Aging; 2009 Mar; 13(3):205-8. PubMed ID: 19262954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies.
    Bogstedt A; Groves M; Tan K; Narwal R; McFarlane M; Höglund K
    J Alzheimers Dis; 2015; 46(4):1091-101. PubMed ID: 26402635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
    Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
    J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fully automated chemiluminescence enzyme immunoassays showing high correlation with immunoprecipitation mass spectrometry assays for β-amyloid (1-40) and (1-42) in plasma samples.
    Yamashita K; Watanabe S; Ishiki K; Miura M; Irino Y; Kubo T; Matsui J; Hagino K; Iwanaga S; Yoshida T
    Biochem Biophys Res Commun; 2021 Oct; 576():22-26. PubMed ID: 34478915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid-β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort.
    Klafki HW; Hafermann H; Bauer C; Haussmann U; Kraus I; Schuchhardt J; Muck S; Scherbaum N; Wiltfang J
    J Alzheimers Dis; 2016 Sep; 54(2):691-705. PubMed ID: 27567847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab.
    Lachno DR; Evert BA; Vanderstichele H; Robertson M; Demattos RB; Konrad RJ; Talbot JA; Racke MM; Dean RA
    J Alzheimers Dis; 2013; 34(4):897-910. PubMed ID: 23302661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New plasma LC-MS/MS assays for the quantitation of beta-amyloid peptides and identification of apolipoprotein E proteoforms for Alzheimer's disease risk assessment.
    Weber DM; Kim JC; Goldman SM; Clarke NJ; Racke MK
    J Investig Med; 2024 Jun; 72(5):465-474. PubMed ID: 38548482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls.
    Pannee J; Portelius E; Oppermann M; Atkins A; Hornshaw M; Zegers I; Höjrup P; Minthon L; Hansson O; Zetterberg H; Blennow K; Gobom J
    J Alzheimers Dis; 2013; 33(4):1021-32. PubMed ID: 23076076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of Amyloid-β in Plasma by Simple and Highly Sensitive Immunoaffinity Enrichment and LC-MS/MS Assay.
    Iino T; Watanabe S; Yamashita K; Tamada E; Hasegawa T; Irino Y; Iwanaga S; Harada A; Noda K; Suto K; Yoshida T
    J Appl Lab Med; 2021 Jul; 6(4):834-845. PubMed ID: 33462584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a Chemiluminescence Immunoassay for Measuring Amyloid-β in Human Blood Plasma.
    Vogelgsang J; Wiltfang J; Klafki HW
    Methods Mol Biol; 2018; 1750():111-124. PubMed ID: 29512068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Label-free detection of β-amyloid peptides (Aβ40 and Aβ42): a colorimetric sensor array for plasma monitoring of Alzheimer's disease.
    Ghasemi F; Hormozi-Nezhad MR; Mahmoudi M
    Nanoscale; 2018 Apr; 10(14):6361-6368. PubMed ID: 29561053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics.
    Lachno DR; Emerson JK; Vanderstichele H; Gonzales C; Martényi F; Konrad RJ; Talbot JA; Lowe SL; Oefinger PE; Dean RA
    J Alzheimers Dis; 2012; 32(4):905-18. PubMed ID: 22886018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Sensitive and Cost-Effective Chemiluminescence ELISA for Measurement of Amyloid-β 1-42 Peptide in Human Plasma.
    Mehta PD; Patrick BA; Miller DL; Coyle PK; Wisniewski T
    J Alzheimers Dis; 2020; 78(3):1237-1244. PubMed ID: 33252086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1-42 peptide in human plasma with utility for studies of Alzheimer's disease therapeutics.
    Song L; Lachno DR; Hanlon D; Shepro A; Jeromin A; Gemani D; Talbot JA; Racke MM; Dage JL; Dean RA
    Alzheimers Res Ther; 2016 Dec; 8(1):58. PubMed ID: 27978855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.